H.C. Wainwright analyst Matthew Keller raised the firm’s price target on Galectin Therapeutics (GALT) to $11 from $6 and keeps a Buy rating on the shares. The firm says recent biomarker data continue to strengthen confidence in Galectin’s metabolic dysfunction-associated steatohepatitis program.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GALT:
- Galectin Therapeutics Holds 2025 Annual Stockholders Meeting
- Galectin Therapeutics Reveals Promising NAVIGATE Trial Results
- Galectin Therapeutics Reports Q3 2025 Financials
- Promising Phase 2 Data Boosts Confidence in Galectin Therapeutics’ Belapectin for Fibrotic Disease Treatment
- Galectin Therapeutics reports Q4 EPS (13c) vs (18c) last year